Horizon2020: First JTI calls
Enlarge image


Horizon2020: First JTI calls

11.07.2014 - Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Seven public-private JTI partnerships that were established under the EU's research funding programme Horizon 2020 have officially launched and presented their first calls for projects and partners. The first round of public funding is worth €1.13bn and will be complemented by a comparable amount from private partners. One of the initiatives aims to develop the European bioeconomy sector: European joint undertaking on Bio-based Industries (BBI). The public-private partnership between the EU and the Bio-based Industries Consortium (BIC) launched the first Call for Proposals worth €50m - excluding industry contributions, which are expected to reach up to €150m. The call contains 16 topics, among them flagship action "Added value products from underutilised agricultural resources". Other actions target products from plant residues or biowaste streams. Over the course of the programme, which will run until 2024, the European Commission will inject €975m, while BIC will invest €2.7bn. BIC said in their press release that the project aims to “use Europe's untapped biomass and wastes as feedstock to make fossil-free and greener everyday products. At the heart of it are advanced biorefineries and innovative technologies that will convert renewable resources into sustainable bio-based chemicals, materials and fuels.” Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, said: "The bioeconomy has huge potential that is attracting investments all around the world. With this new partnership, we want to harness innovative technologies to convert Europe’s untapped renewable resources and waste into greener everyday products."

Red rather than green biotechnology is the focus of the Innovative Medicines Initiative, IMI2. The public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) has a budget of €3.3bn, making it the largest of such partnerships in European healthcare. The first phase of IMI ran between 2008 and 2013 with a budget of €2bn. Roch Doliveux, Chair of the IMI Board, commented: “Health will be a major economic challenge for Europe in the coming decades, and smart investment in healthcare is essential, for the benefit of both EU citizens and EU economies. [...] By bringing together industry and academia, IMI can help us tackle existing healthcare challenges and improve lives for the patients that we are all striving to help.” Paul-Peter Tak, Chair of EFPIA’s Research Directors Group, added: “We expect the outputs of IMI2 to deliver real results for patients. Specifically, IMI2 projects will seek to advance trends in personalised medicines; to further R&D in areas of unmet medical need; and to address the regulatory context in hopes of speeding translation from research to innovation and making new medicines available to patients.”

Watch a video for BBI

Watch a video for IMI


Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.


08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.


04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.


03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.


01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.


30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.


25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.


24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.


20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

© 2007-2014 BIOCOM


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)3.26 SEK5.16%
  • OREXO (S)121.00 SEK4.54%
  • CO.DON (D)2.88 EUR4.35%


  • ANTISOMA (UK)1.32 GBP-14.84%
  • EPIGENOMICS (D)3.06 EUR-8.38%


  • CELLECTIS (F)13.54 EUR112.6%
  • SANTHERA (CH)68.40 CHF107.3%
  • ADDEX (CH)4.40 CHF101.8%


  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.98 EUR-50.3%
  • VERONA PHARMA (UK)1.15 GBP-45.2%


  • SANTHERA (CH)68.40 CHF3009.1%
  • PAION (D)2.80 EUR324.2%


  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014